Thromboembolic and bleeding complications in cancer patients
Lead Institution:
University of Amsterdam
Principal investigator:
Dr Frits Mulder
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Thromboembolism is an obstructing clot in veins or arteries at different locations of the human body. Patients with cancer frequently suffer from this complication, which can lead to death or decreased quality of life. In order to prevent this complication, preventive anticoagulant therapy can be prescribed (thromboprophylaxis). In order to only select patients at high risk of thromboembolism, risk scores are used. The performance of these scores is not yet optimal which directly influences the effect of thromboprophylaxis. Current study will use the genetic (and clinical) data of the UK biobank with the goal to improve the currently existing prediction models. By improving the score, more patients will benefit from thromprophylaxis and less patients will suffer from thromboembolism. The project will take approximately 12-24 months.